Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-78898A in Exudative AMD
NCT01157065Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AL-78898A in exudative age-related macular degeneration (2 arms), sponsored by Alcon Inc. Primary endpoints: Mean Reduction From Baseline in Central Subfield Retinal Thickness at 4 weeks and Incidence of Events of Special Interest at 30 days. Started Jun 2011; status: completed.
02
Drugs
AL-78898A
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01157065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157065.